Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$20.41
+1.7%
$17.91
$13.53
$35.25
$2.05B2.071.56 million shs827,150 shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$57.89
-0.2%
$54.68
$42.01
$70.51
$7.14B1.151.75 million shs506,815 shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$2.31
+3.4%
$1.91
$1.64
$12.51
$769.04M0.859.39 million shs16.21 million shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$5.11
+7.8%
$3.87
$1.92
$11.60
$270.87M2.28349,361 shs291,074 shs
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
$178.75
$176.25
$108.82
$189.99
$10.93B0.13572,759 shsN/A
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
+2.50%-6.48%+20.76%+18.06%-26.46%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+2.49%+2.53%+7.59%-1.33%+5.28%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
+14.95%+12.06%+7.21%-27.00%-76.30%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-1.46%+6.76%+26.74%+66.67%+46.30%
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.2327 of 5 stars
3.50.00.00.03.12.50.6
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
4.8458 of 5 stars
2.14.00.04.42.92.54.4
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
4.6212 of 5 stars
4.21.00.04.22.94.20.6
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
4.0545 of 5 stars
3.02.00.04.63.13.30.0
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.00
Buy$48.75138.88% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.17
Hold$62.708.32% Upside
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.33
Hold$12.22430.25% Upside
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.00
Hold$9.0076.09% Upside
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest HALO, IOVA, KOD, XLRN, and BEAM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$58.00 ➝ $60.00
7/15/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Sell
7/10/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$55.00
5/29/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00
5/16/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$17.00 ➝ $2.00
5/14/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$73.00 ➝ $62.00
5/13/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
5/13/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform ➝ Underperform$47.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $8.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $10.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$63.52M32.31N/AN/A$8.86 per share2.30
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.02B7.02$4.76 per share12.17$2.86 per share20.24
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$164.07M4.69N/AN/A$2.33 per share0.99
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$2.86 per shareN/A
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
$92.52M118.15N/AN/A$11.74 per share15.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$376.74M-$4.61N/AN/AN/A-609.24%-44.24%-30.97%8/5/2025 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$444.09M$3.7615.419.310.3844.76%136.91%26.05%8/5/2025 (Estimated)
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$372.18M-$1.24N/AN/AN/A-176.49%-49.71%-39.18%8/6/2025 (Estimated)
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
-$166.03M-$4.21N/AN/AN/A-226.01%-32.11%-29.45%N/A

Latest HALO, IOVA, KOD, XLRN, and BEAM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.29N/AN/AN/AN/AN/A
8/13/2025Q2 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$1.01N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.04N/AN/AN/A$13.29 millionN/A
8/5/2025Q2 2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.22N/AN/AN/A$282.66 millionN/A
5/14/2025Q1 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.89-$1.09-$0.20-$1.09N/AN/A
5/8/2025Q1 2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million
5/6/2025Q1 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million
5/6/2025Q1 2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.98$1.11+$0.13$0.93$231.21 million$264.86 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
8.81
8.81
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
3.13
8.39
7.30
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
4.18
3.64
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
4.62
4.62
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
N/A
12.14
12.14

Institutional Ownership

CompanyInstitutional Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
90.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510100.56 million97.04 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
390123.22 million120.26 millionOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
500333.93 million299.54 millionOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
9052.76 million28.55 millionOptionable
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
31261.16 million60.12 millionOptionable

Recent News About These Companies

Acceleron advances cold fusion technology
Acceleron Banks on Muons for Colder Fusion
Acceleron attracts turbocharged demand for debut Swissie
Merck confirms $11.5bn Acceleron takeover deal
ORBIMED CAPITAL GP II LLC's Net Worth
XLRN Historical Data
MSD eyes March FDA decision on PAH drug sotatercept
Astellas Pharma Inc
HempStreet partners with MGC Pharma launches ArtemiC
Acceleron Corp Becomes a Digital Correspondent Bank
Pharma Contract Sales Market Report 2022-2032

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$20.41 +0.34 (+1.68%)
As of 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$57.88 -0.13 (-0.22%)
As of 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$2.31 +0.08 (+3.36%)
As of 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$5.11 +0.37 (+7.83%)
As of 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Acceleron Pharma stock logo

Acceleron Pharma NASDAQ:XLRN

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.